What is Adimab?
Adimab is a prominent biotechnology company specializing in a yeast-based platform for the discovery and engineering of therapeutic antibodies. The company provides a comprehensive suite of services, including antibody discovery, optimization, and the development of multispecific antibodies, all aimed at accelerating the creation of novel treatments. With a robust portfolio of over 140 biopharma partnerships, Adimab has demonstrated a consistent ability to advance therapeutic programs through flexible collaboration models. Founded in 2007, the company's expertise in antibody engineering and its commitment to partner success have solidified its reputation as a key player in the biopharma industry.
How much funding has Adimab raised?
Adimab has raised a total of $32M across 4 funding rounds:
Series A
$6M
Series D
$8.2M
Series E
$4M
Series F
$13.8M
Series A (2007): $6M with participation from SV Health Investors and Polaris Partners
Series D (2010): $8.2M led by OrbiMed, SV Life Sciences, Google Ventures, Borealis Ventures, and Polaris Partners
Series E (2010): $4M, investors not publicly disclosed
Series F (2012): $13.8M featuring SV Life Sciences, Polaris Partners, and Google Ventures
Key Investors in Adimab
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, and diagnostics. The firm's investment approach reflects a comprehensive understanding of healthcare innovation cycles and market dynamics, supporting companies at various stages of development.
SV Life Sciences
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
Google Ventures
GV is a venture capital firm that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, consumer products, and frontier technology innovations. GV operates globally, providing financial backing to promising startups and growth-stage businesses.
What's next for Adimab?
The substantial enterprise-level funding and recent strategic investment indicate Adimab's strong market position and the confidence investors have in its proprietary technology and business model. This capital infusion is expected to fuel further expansion of its discovery and engineering capabilities, potentially enabling Adimab to tackle more complex therapeutic challenges and broaden its partnership base. The company's focus on flexible collaboration suggests a strategy geared towards sustained growth and the development of a diverse pipeline of antibody-based therapeutics, reinforcing its trajectory as a critical enabler of next-generation medicines.
See full Adimab company page
